Summary
The blood-brain barrier (BBB) is an essential gatekeeper for the central nervous system and incidence of neurodevelopmental disorders (NDDs) is higher in infants with a history of intracerebral hemorrhage (ICH). We discovered a rare disease trait in thirteen individuals, including four fetuses, from eight unrelated families associated with homozygous loss-of-function variant alleles of ESAM which encodes an endothelial cell adhesion molecule. The c.115del (p.Arg39Glyfs∗33) variant, identified in six individuals from four independent families of Southeastern Anatolia, severely impaired the in vitro tubulogenic process of endothelial colony-forming cells, recapitulating previous evidence in null mice, and caused lack of ESAM expression in the capillary endothelial cells of damaged brain. Affected individuals with bi-allelic ESAM variants showed profound global developmental delay/unspecified intellectual disability, epilepsy, absent or severely delayed speech, varying degrees of spasticity, ventriculomegaly, and ICH/cerebral calcifications, the latter being also observed in the fetuses. Phenotypic traits observed in individuals with bi-allelic ESAM variants overlap very closely with other known conditions characterized by endothelial dysfunction due to mutation of genes encoding tight junction molecules. Our findings emphasize the role of brain endothelial dysfunction in NDDs and contribute to the expansion of an emerging group of diseases that we propose to rename as “tightjunctionopathies.”
Keywords: ESAM, tight junctions, blood-brain barrier, neurodevelopmental disorders, intracranial hemorrhage, global developmental delay, intellectual disability, epilepsy, retinopathy, pregnancy loss, exome sequencing
Graphical abstract
We identified homozygous loss-of-function variants in ESAM, encoding an endothelial cell adhesion molecule, in thirteen individuals (including four fetuses) showing intracerebral hemorrhage in prenatal age and neurodevelopmental disorders. Our findings contribute to expand an emerging group of diseases caused by alterations of tight-junction genes (e.g., JAM2, JAM3, OCLN).
Main text
Neurodevelopmental disorders (NDDs) are a large group of disabilities involving impairment of the brain and neurocognitive development affecting >3% of children worldwide.1 NDDs include a broad spectrum of phenotypes such as intellectual disability/developmental delay (ID/DD), autism spectrum disorders (ASD), attention-deficit/hyperactivity disorder (ADHD), epilepsy, cerebral palsy, and language impairment. Comorbidity of two or more of these conditions is frequently observed.2 Furthermore, neuroimaging findings, such as corpus callosum and white matter anomalies, may suggest a specific etiology for NDD.3 At least 30% of NDDs are thought to have a genetic basis, and a plethora of genes and molecular alterations have been identified, underlying wide clinical and genetic heterogeneity, overlapping phenotypes, and gene pleiotropy, which together make molecular diagnosis a challenging task.4,5 The implementation of next-generation sequencing (NGS) technologies, especially exome sequencing (ES), which has been proposed as a first-tier test in the diagnostic algorithm of all NDDs followed by array-CGH when necessary, has dramatically increased the percentage of NDD-affected individuals who receive a molecular diagnosis.6 Furthermore, diagnostic rates reported in recent studies and meta-analyses are 30%–40% or higher when trio analysis is performed and when NDD-affected individuals eligible for diagnostic ES are prioritized before testing based on their phenotypic presentation.7,8,9,10,11,12,13
Prenatal/perinatal brain damage due to intracranial/intraventricular hemorrhage (ICH/IVH) is one of the leading causes of lifelong disability, including cerebral palsy, epilepsy, sensory impairment, and cognitive deficit.14,15,16,17,18 The blood-brain barrier (BBB), whose integrity is maintained by junctional adhesion molecules (JAMs), is considered the core structure of the neurovascular unit (NVU) and plays a critical role in maintaining central nervous system homeostasis. Tight junctions (TJs) are an essential BBB component and bi-allelic variants in the tight-junction genes JAM2/3 (junctional adhesion molecule 2/3 [MIM: 606870 and 606871]) and OCLN (occludin [MIM: 602876]) have been implicated in individuals with compromised BBB permeability. These subjects typically show a combination of brain hemorrhage and calcification together with movement disorders and cognitive and neurobehavioral manifestations.19,20,21,22,23,24
In this study, we identified bi-allelic variants in ESAM (endothelial cell adhesion molecule [MIM: 614281]), a gene not previously associated with a rare disease trait in humans, which encodes a TJ protein related to JAM proteins involved in the formation and maintenance of the BBB. Genotypic (ES) and clinical phenotypic data from individuals with ESAM variants were recruited through GeneMatcher25 and our international collaborative network. All individuals were carefully evaluated by a multidisciplinary team of pediatric neurologists/neuro-ophthalmologists/neuroradiologists and clinical geneticists of their respective referral center. We collected clinical information related to neurodevelopment, growth parameters, dysmorphology, neurological, ocular, and vascular manifestations, plus behavior and neuroimaging. No formal intelligence testing was possible in individuals over the age of 5 years because of the severe global developmental delay, including complete lack of language and motor skills. Written human subject research informed consent for genetic analysis and publication of the clinical information, including relevant clinical pictures, was obtained from the parents or legal guardians of each research subject according to the Declaration of Helsinki and Institutional Review Boards of participating research centers.
The age of affected individuals included in the study, 8 males and 4 females (sex was unknown in a 32-week-old fetus), ranged from 31 weeks of gestation to 13 years. Onset of symptoms occurred in the antenatal/neonatal period. Global developmental delay/unspecified intellectual disability (GDD/UID), absent or severely delayed speech, epilepsy, spasticity (mainly consisting of spastic tetraparesis), hypotonia (which frequently occurred neonatally), and dilation of lateral ventricles were observed in all nine live-born children, the latter being also noted in the four fetuses examined in the study (Table S1), while variable microcephaly was reported in four out of nine children (mean OFC Z score: −3.35; range: −2.1 to −5.7). Following dilation of lateral ventricles, thinning of the corpus callosum, hydrocephalus, and focal white matter lesions were the most frequently observed neuroimaging abnormalities (eight, seven, and five individuals, respectively) (Figure 1). Notably, hydrocephalus was a feature also observed in all fetuses as well as in a previously reported individual carrying an ESAM homozygous nonsense variant (Table S1).26 Intracranial hemorrhages (ICH) or suspected cerebral microangiopathy, frequently associated with cerebral calcifications (Figure 1), were reported in all individuals, including the four fetuses. Other vascular anomalies were represented by retinal hemorrhage (four individuals)—due to increased tortuosity of retinal vasculature (Figures S1 and S2)—and renal medullary hemorrhage (in a 31-week stillbirth). Dysmorphic facial features were noted in most individuals, mainly consisting of bitemporal narrowing (6/9), highly arched eyebrow and bulbous nasal tip, which were detected with the same frequency (5/9), followed by presence of long eyelashes (4/9), abnormal vermilion (4/9), high narrow palate (3/9), wide nasal bridge (3/9), upslanted palpebral fissures (3/9), and microretrognathia (2/9), the latter being also present in a fetus (Table S1 and supplemental note).
Figure 1.
Neuroimaging abnormalities in individuals with homozygous ESAM variants
Individual 1: T1-weighted (a and b) images showing various parenchymal hemorrhagic area in different evolution phases, located at the parietal-occipital area. T2-weighted and multi-echo gradient-recalled echo (GRE) T2-weighted images (c and d) showing blood occupying the ventricular spaces (hemoventricle). T1-weighted MRI (e and f) and FLAIR sequences (g) highlight a dysmorphic corpus callosum (e) and poromalacic evolution of the hemorrhagic areas with ventricular dilatation (f and g) and diffuse subependymal microhemorrhage foci. The orange arrow in (g) indicates ventricular derivation.
Individual 4: MRI images at 2 days after birth: 3DT2 sagittal (a), 3DT2 coronal MPR (b), 3DT1 axial (c), 3D TOF (d). Bilateral grade III germinal matrix - intraventricular hemorrhage (blue arrows) with supratentorial posthemorrhagic hydrocephalus. Bilateral parenchymal hematomas with associated subpial hemorrhages (orange arrows) at different stages and parietal encephalomalacia secondary to prior bleeding with residual clot inside (red stars). No evident vascular anomalies in MRI angiography (3D TOF sequence) were found.
Individual 5 (sibling of individual 4): MRI images at 7 days after birth: 3DT2 sagittal (a), 3DT2 coronal MPR (b), 3DT1 axial (c), 3D TOF (d). Microcephaly with simplified gyral pattern and severe hypoplastic corpus callosum (blue arrow). Left parietal subcortical white matter hematoma with subpial hemorrhage (red stars) and encephalomalacia. Right frontal (orange arrow) and multiple bilateral periventricular hemorrhages. MRI angiography (3D TOF sequence) shows slight narrowing of the proximal anterior and middle cerebral arteries (green arrows).
Individual 6: MRI images at 5 days old. T1- (a) and T2- (b) weighted images showing massive dilatation of lateral ventricles with global cerebral parenchymal destruction. Diffuse meningeal and intraventricular hemorrhage with intraventricular clotting. Focal destruction of the septum pellucidum.
Individual 8: axial T2-weighted images showed hyperintensity and volume loss in the bilateral periventricular white matter, frontotemporal atrophy, dilatation in the lateral ventricles (a and b) and hypoplasia of the corpus callosum (c) (orange arrows). Bilateral periventricular calcifications were observed on cranial CT (d), as indicated by the arrow.
Individual 9: Head CT (axial) showing bilateral subependymal (a) and basal ganglia/thalamus calcifications (b) (orange arrows), suggestive of a previous bleeding. Dilation of the lateral ventricles and their straight shape suggest agenesis of the corpus callosum, as confirmed in the sagittal multiplanar reformation (c).
Individual 11: Axial T2-weighted true fast sequence (a and b), axial T2 HASTE sequence (c), and axial T1-weighted sequence (d). The fetal brain MRI shows hydrocephalus, intraventricular hemorrhage, diffuse intraparenchymal, and periventricular hemorrhages with calcifications (hypointense signals on T1-weighted images).
Individual 13: Brain MRI at 37 weeks of gestation. Axial T2 (a and b) showing severe irregular ventriculomegaly with increased extra-axial spaces and significant decrease in gray and white matter volume. Orange arrows indicate an abnormal Sylvian fissure development in (a) and an asymmetric gyral pattern suggestive of dysgyria/polymicrogyria in (b). Small periventricular cysts are indicated by red stars. Sagittal T2 (c) highlighting corpus callosum dysgenesis with absence of rostrum (arrow). Coronal T2 (d): hypointense lesions in the temporal parenchyma (indicated by the arrow) protruding into the temporal horn of the right ventricle. GRE T2 sequences (e) demonstrate susceptibility artifacts consistent with brain calcification (arrow).
ES identified homozygous ESAM loss-of-function (LoF) variant alleles in all affected individuals belonging to eight independent families (from A to H) (Figure 2 and supplemental note). The same frameshift variant in exon 2, c.115del (p.Arg39Glyfs∗33), was detected in six individuals from four unrelated families, including a 31-week stillbirth (individuals 1, 2, 3, 7, 8, and 10). Individuals 4 and 5 are affected siblings carrying the c.287del (p.Pro96Leufs∗33) frameshift variant in exon 3. Individual 6 harbored a nonsense variant within the first gene exon, c.35T>A (p.Leu12∗). Although archival autopsy material was not available for his affected sibling (individual 11), a fetus of 32 weeks, it is highly likely that the same variant was present based on strict phenotypic comparison. Individuals 9, 12, and 13 carried the same homozygous splice variant in intron 3 (c.451+1G>A) predicted to cause loss of donor splice site by multiple in silico tools (e.g., HSF, MaxEntScan, SpliceAI, CADD-Splice). In all probands no other potentially relevant variants were identified either in known genes associated with neurological and vascular conditions/phenotypes, according to PanelApp, HPO, and GTR, or by filtering the variants for coherent inheritance patterns.
Figure 2.
Family pedigrees and genetic findings
Bi-allelic ESAM variants are shown in thirteen affected individuals, including four fetuses, from eight unrelated families. The c.115del (p.Arg39Glyfs∗33) frameshift variant was identified in six individuals from families A, B, E, and F, originating from the same geographic area in Turkey (southeastern Anatolia). The c.287del (p.Pro96Leufs∗33) frameshift variant was detected in two affected siblings from Spain (family C). The c.35T>A (p.Leu12∗) nonsense variant was identified in a family of Algerian descent (family D). The c.451+1G>A splice site variant was identified in two independent families of Arab Bedouin descent (families G and H). +/+, +/−, and −/− represents homozygosity for the wild-type allele, heterozygosity, and homozygosity for the mutant allele, respectively. An asterisk beneath an individual indicates that ES was performed. Arrowheads indicate the probands. TOP, termination of pregnancy; SB, stillbirth; SAB, spontaneous abortion; wks, weeks of gestation.
Interestingly, all individuals harboring the c.115del variant originated from the same geographic region in Turkey (southeastern Anatolia), suggesting a founder effect. The variant was not reported in the SHGP (Saudi Human Genome Program) database, the largest genome repository in the Middle East,27,28 nor in the Iranome database,29 the GME (Greater Middle East) Variome Project,30 or the Turkish Variome (TRV) database.31 Similarly, the c.451+1G>A variant was detected in three individuals from two independent families with the same ethnic origin (Arab Bedouin) and was also absent in the aforementioned databases.
All the variants were classified as likely pathogenic according to the ACMG/AMP criteria (PVS1+PM2) and were predicted to trigger nonsense-mediated mRNA decay (NMD). In all cases, ESAM was embedded in ROH/AOH (runs of homozygosity/absence of heterozygosity) stretches spanning from 1.8 to 13.85 Mb in size, consistent with shared ancestry and/or recent consanguinity. Details of the variants are publicly available in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) with the following accession numbers: SCV002818296 (c.115del), SCV002818297 (c.287del), SCV002818299 (c.35T>A), and SCV002818300 (c.451+1G>A). The predicted 3D structures of the mutant protein products are shown in Figure S3. The crucial immunoglobulin-like (Ig) domains (aa 30–150 and 157–239) and the helical transmembrane domain (aa 247–279) were abolished, whereas the putative motifs predicted by AlphaFold (https://alphafold.ebi.ac.uk/), which are absent in the wild-type protein, did not match with any known protein signature explored through different databases and bioinformatic tools (e.g., Motif Scan, ScanProsite, BlastP).
Considering the crucial role of ESAM in angiogenesis, endothelial permeability, and leukocyte transmigration32,33 as well as its enriched expression in the endothelium (GTEx, BioGPS, HPA) and the peculiar vascular alterations observed in the identified individuals harboring ESAM variants (especially of the brain), we assessed the capability of endothelial progenitors (endothelial colony-forming cells [ECFCs]) to form capillary-like structures in vitro. Compared to an age- and sex-matched control sample, ECFCs of individual 1 showed dramatic phenotypical changes of proliferation, migration, and tubulogenesis (Figure 3A) in terms of both number of branch points and tube length (Figures 3B and 3C), which were almost completely abrogated. On the other hand, the ECFCs isolated from her healthy heterozygous parents showed comparable values to the control sample.
Figure 3.
In vitro matrigel tubulogenesis assay
(A) Endothelial colony-forming cells (ECFCs) isolated from individual 1 showed significantly decreased tubulogenesis compared to the ECFCs obtained from a healthy control (HC) and parents of individual 1.
(B and C) Quantification of tubulogenesis was performed considering the number of branch points (B) and the tube length (C). Data shown (±SD) are from 3 independent experiments. ∗∗p < 0.01. Scale bar: 200 mm. More technical details are provided in the supplemental note.
The fetal brain of individual 10, carrying the c.115del (p.Arg39Glyfs∗33) homozygous frameshift variant, showed lack of ESAM staining in the capillary endothelial cells (Figure 4A), which is consistent with the LoF effect of the c.115del bi-allelic variant. On the other hand, intense expression of ESAM was observed in the cerebral endothelium of an age- and sex-matched control sample, where it was abundantly localized in the plasma membrane of endotheliocytes (Figure 4B). The immunohistochemical findings are in agreement with the results of reverse transcription polymerase chain reaction (RT-PCR) performed on ECFCs of individual 1, showing no detectable ESAM expression (Figure S4), as well as with the in silico NMD predictions and the 3D-modeling, which overall indicate a lack of functional protein. Furthermore, microscopic and histochemical analysis revealed periventricular leukomalacia (Figure 4C) and brain calcification with abundant presence of so-called "ferruginated" neurons, implying mineralization of neurons as a consequence of hypoxic-ischemic damage (Figure 4D).
Figure 4.
ESAM immunohistochemistry and hematoxylin and eosin staining in the damaged brain tissue (white matter) of individual 10
(A and B) A capillary with ESAM-negative endothelial cells in the proband (A) compared to a control sample (B), as indicated by the blue arrows. Magnification: 40 HPF.
(C) Periventricular leukomalacia in individual 10: the white matter close to the lateral ventricle (V) shows multiple areas of calcification (blue arrow). Hematoxylin and eosin staining, magnification 4 HPF.
(D) Calcified areas showing elongated sticks and round bodies as a result of encrusted (“ferruginated”) neurons and their axons with mineral salts. Hematoxylin and eosin staining, magnification 20 HPF. More technical details are provided in the supplemental note.
In this study, we describe a severe neurodevelopmental rare disease trait caused by homozygous LoF variants of ESAM in thirteen individuals, including four fetuses, from eight unrelated families. Global developmental delay/unspecified intellectual disability (GDD/UID) with absent or severely delayed speech, epilepsy, varying degrees of spasticity, ventriculomegaly, and intracranial hemorrhage constitute the cardinal clinical features of the ESAM-related phenotype, being observed in all live-born individuals. Other notable clinical signs were thin corpus callosum and variable microcephaly. Among the clinical features, intracranial hemorrhage, together with hydrocephalus and cerebral calcifications, represented the first observable prenatal anomalies that prompted further genetic investigations and, thus, is hypothesized as the etiological trigger of downstream neurodevelopmental defects. In addition to the frank neurological manifestations, ESAM alterations also appear to cause a well-defined spectrum of ophthalmological signs, particularly retinal ischemia and abnormal retinal vascular morphology.
ESAM encodes an endothelial cell-selective adhesion molecule, a member of the immunoglobulin receptor family, which mediates homophilic interactions between endothelial cells. Previous studies demonstrated that ESAM expression is primarily restricted to embryonic and adult vasculature, where it regulates endothelial permeability and neutrophil extravasation.33,34,35 Mouse model experiments showed that ESAM regulates albumin extravasation at the glomeruli and plays a role in the initiation of diabetic nephropathy.36 A recent proteomic study of individuals affected by diabetic kidney disease confirmed ESAM as a candidate circulating biomarker to predict the risk of progression to kidney failure.37 In this regard, we did not observe renal dysfunction in our pediatric subjects, although later manifestations cannot be completely ruled out and careful follow-up in the next years would be indicated. Interestingly, a proteomic analysis revealed that ESAM interacts with endoglin,38 encoded by ENG, whose mutation causes hereditary hemorrhagic telangiectasia (HHT [MIM: 187300]), a condition that includes ICH as a clinical feature.
In a previous study, a de novo heterozygous frameshift variant in ESAM exon 4, c.543_546dup (p.Val183Argfs∗48), was reported in a 23-year-old male individual affected by schizophrenia and developmental delay.39 Therefore, it could be hypothesized that monoallelic LoF variants in ESAM may at most contribute (possibly together with other factors) to mild neurological phenotypes, in contrast to the severe phenotype we observed in all our homozygous probands. Nevertheless, we did not observe overt neuropsychiatric features in any of our probands' heterozygous parents nor in other carrier family members. This finding is in line with the gene constraint metrics (pLI: 0.20; LOEUF: 0.59; sHet: 0.05; %HI: 63.38) and the presence of an ∼34 kb deletion encompassing ESAM in the DGV (Database of Genomic Variants) repository (nsv556487), indicating that ESAM is quite tolerant to haploinsufficiency, as it is for triplosensitivity (pTriplo: 0.28).40 Altogether, it is at most possible to speculate that heterozygous LoF variants may represent a susceptibility factor characterized by incomplete penetrance, and, in any case, further studies are needed to better address this point.
Our in vitro tubulogenesis assays recapitulated findings in null mice (Esam−/−) where a decrease of tube formation and vascular density was documented, although without overt morphological defects of the vasculature.32 On the contrary, we observed a high frequency of vascular manifestations (intracranial hemorrhage, cerebral calcifications, focal white matter lesions, hydrocephalus, and dilation of lateral ventricles), in agreement with the critical role of ESAM in endothelial homeostasis. The fact that both null mice and human subjects carrying homozygous LoF variants in ESAM show a non-lethal (although extremely severe) phenotype could potentially be explained considering the redundant functional role of ESAM in physiological angiogenesis and the presence of other endothelial adhesion molecules which may compensate for its dysfunction.
It is noteworthy that the phenotype associated with bi-allelic variants of ESAM overlaps very closely with other known conditions characterized by endothelial dysfunction due to mutation of genes encoding tight junction molecules, namely JAM2, JAM3, and OCLN. Bi-allelic LoF variants of JAM2 are associated with idiopathic basal ganglia calcification (IBGC8 [MIM: 618824]), a condition commonly characterized by intracerebral calcifications, cognitive decline, learning difficulties, seizures, slurred speech, movement disorders, and psychiatric symptoms.19,20 Homozygous LoF variants in JAM3 have been identified in individuals with multifocal intraparenchymal hemorrhage and subependymal calcification as cardinal features (HDBSCC [MIM: 613730]), accompanied by reduced white matter volume, porencephaly, and massive cystic degeneration resulting in enlarged ventricles.21,22 In most of the cases, this condition is extremely severe, with death occurring in the first few weeks of life, while alive individuals develop profound developmental delay, microcephaly, generalized spasticity, and seizures, as we observed in our cohort of affected individuals. Finally, bi-allelic LoF variants affecting a tight junction protein, occludin, have been reported in individuals showing profound developmental delay, early-onset seizures, microcephaly, ventriculomegaly, spasticity, polymicrogyria, loss of white matter, and intracranial calcifications, referred to as pseudo-TORCH syndrome 1 (PTORCH1 [MIM: 251290]).23,24 Overall, neurological manifestations (namely DD, seizures, spasticity, and hypotonia) and intracranial calcifications represent the cardinal clinical features shared among these conditions, which we also observed in ESAM-affected individuals, whereas ICH seems specifically restricted to JAM3- and ESAM-related phenotypes (Table 1). Furthermore, individuals with pathogenic variants in COL4A1, encoding type IV collagen alpha-1 chain protein (a vascular basement membrane protein highly expressed in brain vessels), show intracerebral hemorrhage with calcifications, porencephaly, cystic brain lesions, hydrocephalus, seizures, and retinal arterial tortuosity.41,42,43,44,45 In aggregate these data suggest that defective cell adhesion and solute flux through the paracellular spaces in the neurovascular unit (NVU) is a key pathomechanism of brain calcification and hemorrhage in this group of disorders, which we here propose to rename as “tightjunctionopathies.”
Table 1.
Phenotypic comparison of individuals with bi-allelic variants in JAM2, JAM3, OCLN, and ESAM
Clinical features | JAM2 | JAM3 | OCLN | ESAM |
---|---|---|---|---|
Head and neck | ||||
Microcephaly | no | yes | yes | yes |
Cataracts | no | yes | yes (rare) | no |
Facial dysmorphisms | no | no | yes: long philtrum, microretrognathia, low-set ears, anteverted nares, high arched palate | yes: bitemporal narrowing, highly arched eyebrow, bulbous nasal tip, long eyelashes, high narrow palate, wide nasal bridge, upslanted palpebral fissures, microretrognathia, anteverted nares |
Neurologic | ||||
Developmental delay | yes | yes (severe) | yes (severe) | yes (severe) |
Seizures | yes (rare) | yes | yes | yes |
Spasticity | yes | yes | yes | yes |
Hypotonia | no | yes | yes | yes |
Neuroimaging findings | ||||
Intracranial calcifications | yes | yes | yes | yes |
Intracranial hemorrhage | no | yes | no | yes |
Ventriculomegaly | no | yes | yes | yes |
Corpus callosum anomalies | no | yes | yes | yes |
Abdomen | ||||
Hepatomegaly | no | yes | yes | no |
Genitourinary | ||||
Renal anomalies | no | yes (rare) | yes (rare) | yes (rare) (renal medullary hemorrhage) |
Disease onset | adulthood | neonatal | neonatal | antenatal/neonatal |
Prenatal ICH is a strong risk factor for perinatal mortality and adverse neurodevelopmental outcome. In a recent systematic review, cerebral palsy (CP) was observed at postnatal follow-up in 32% of fetuses with prenatal diagnosis of ICH, in most cases accompanied by severe neurodevelopmental delay.18 Accordingly, we observed varying degrees of spasticity (mainly consisting of spastic tetraparesis) in all children with bi-allelic ESAM variants, together with GDD/UID and other neurological manifestations. Genetic testing is rarely considered in the diagnostic workup of CP individuals, although a recent systematic review and meta-analysis reported non-negligible diagnostic yields of ES and CMA (23% and 5%, respectively).46 Our findings add a piece of knowledge to the genetic causes of CP conferring vulnerability to brain injury during prenatal life and causing long-term neurodevelopmental complications.
In summary, our study reveals a rare Mendelian condition associated with bi-allelic ESAM variants and emphasizes the increasingly emerging role of brain endothelial dysfunction in neurodevelopmental disorders. In fact, the interplay between vascular and neuronal systems is critical for the normal growth and function of neurons, considering that brain development relies heavily on proper cerebrovascular maturation forming a complex system of multidirectional communication known as the “neuro-glial-vascular” unit.47,48,49,50 Therefore, it is conceivable that alterations in cerebrovascular processes during early development may have long-lasting neurodevelopmental consequences, including non-malformative conditions. In fact, endothelial dysfunction leading to impaired cerebral angiogenesis has been documented in a mouse model hemizygous for the ASD-related 16p11.2 deletion, pointing to a potential role for endothelial impairment in ASD pathogenesis.51 In this regard, a previous ASD postmortem brain study suggested an impairment in cerebral angiogenesis,52 whereas a functional imaging study proposed a possible link between ASD and altered cerebral blood flow.53 Altogether, these data also open a new perspective on potential treatment options for mitigating endothelial cell dysfunction in neurodevelopmental conditions due to altered BBB function.
Acknowledgments
The authors thank all probands and families for their participation in this study. More details are provided in the supplemental note.
Author contributions
M.L.: Data curation, Investigation, Validation, Visualization; D.P., D.H.S., K.W., T.C., M.Z., Y.O., N.D.-F.: Funding acquisition, Investigation, Validation, Supervision; V.R., M.P.B., A.M., R.Z., D.M., T.M., J.E.P., J.H.-R., E.A.C., E.M., C.V.B., E.S.: Investigation; G.C., M.P., R.P., A.N., C.F., S.E.B., A.G., J.R.-B., M.A.R., L.B.S., S.S., A. Begemann, S.U., S.G., S.H., Y.Z., M.J.: Resources; A. Balduini, O.Z., R.H., H.L., A.R., L.G., E.T.-L., R.S., J.R.L.: Supervision, Funding acquisition, Writing – review & editing; E.E.: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing
Declaration of interests
J.R.L. has stock ownership in 23andMe and is a paid consultant for the Regeneron Genetics Center.
Published: March 29, 2023
Footnotes
Supplemental information can be found online at https://doi.org/10.1016/j.ajhg.2023.03.005.
Web resources
OMIM, https://www.omim.org/
Supplemental information
Data and code availability
The published article includes all datasets generated or analyzed during this study. In particular, details of the variants are publicly available in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) with the following accession numbers: SCV002818296 (c.115del), SCV002818297 (c.287del), SCV002818299 (c.35T>A), and SCV002818300 (c.451+1G>A).
References
- 1.Olusanya B.O., Wright S.M., Nair M.K.C., Boo N.Y., Halpern R., Kuper H., Abubakar A.A., Almasri N.A., Arabloo J., Arora N.K., et al. Global burden of childhood epilepsy, intellectual disability, and sensory impairments. Pediatrics. 2020;146:e20192623. doi: 10.1542/peds.2019-2623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Parenti I., Rabaneda L.G., Schoen H., Novarino G. Neurodevelopmental disorders: from genetics to functional pathways. Trends Neurosci. 2020;43:608–621. doi: 10.1016/j.tins.2020.05.004. [DOI] [PubMed] [Google Scholar]
- 3.Engbers H.M., Nievelstein R.A.J., Gooskens R.H.J.M., Kroes H.Y., van Empelen R., Braams O., Wittebol-Post D., Hendriks M.M.W.B., Visser G. The clinical utility of MRI in patients with neurodevelopmental disorders of unknown origin. Eur. J. Neurol. 2010;17:815–822. doi: 10.1111/j.1468-1331.2009.02927.x. [DOI] [PubMed] [Google Scholar]
- 4.Retterer K., Juusola J., Cho M.T., Vitazka P., Millan F., Gibellini F., Vertino-Bell A., Smaoui N., Neidich J., Monaghan K.G., et al. Clinical application of whole-exome sequencing across clinical indications. Genet. Med. 2016;18:696–704. doi: 10.1038/gim.2015.148. [DOI] [PubMed] [Google Scholar]
- 5.Mitani T., Isikay S., Gezdirici A., Gulec E.Y., Punetha J., Fatih J.M., Herman I., Akay G., Du H., Calame D.G., et al. High prevalence of multilocus pathogenic variation in neurodevelopmental disorders in the Turkish population. Am. J. Hum. Genet. 2021;108:1981–2005. doi: 10.1016/j.ajhg.2021.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Srivastava S., Love-Nichols J.A., Dies K.A., Ledbetter D.H., Martin C.L., Chung W.K., Firth H.V., Frazier T., Hansen R.L., Prock L., et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet. Med. 2019;21:2413–2421. doi: 10.1038/s41436-019-0554-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Thevenon J., Duffourd Y., Masurel-Paulet A., Lefebvre M., Feillet F., El Chehadeh-Djebbar S., St-Onge J., Steinmetz A., Huet F., Chouchane M., et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin. Genet. 2016;89:700–707. doi: 10.1111/cge.12732. [DOI] [PubMed] [Google Scholar]
- 8.Vrijenhoek T., Middelburg E.M., Monroe G.R., van Gassen K.L.I., Geenen J.W., Hövels A.M., Knoers N.V., van Amstel H.K.P., Frederix G.W.J. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur. J. Hum. Genet. 2018;26:1566–1571. doi: 10.1038/s41431-018-0203-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Geisheker M.R., Heymann G., Wang T., Coe B.P., Turner T.N., Stessman H.A.F., Hoekzema K., Kvarnung M., Shaw M., Friend K., et al. Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains. Nat. Neurosci. 2017;20:1043–1051. doi: 10.1038/nn.4589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Lindstrand A., Eisfeldt J., Pettersson M., Carvalho C.M.B., Kvarnung M., Grigelioniene G., Anderlid B.M., Bjerin O., Gustavsson P., Hammarsjö A., et al. From cytogenetics to cytogenomics: whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability. Genome Med. 2019;11:68. doi: 10.1186/s13073-019-0675-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Martinez-Granero F., Blanco-Kelly F., Sanchez-Jimeno C., Avila-Fernandez A., Arteche A., Bustamante-Aragones A., Rodilla C., Rodríguez-Pinilla E., Riveiro-Alvarez R., Tahsin-Swafiri S., et al. Comparison of the diagnostic yield of aCGH and genome-wide sequencing across different neurodevelopmental disorders. NPJ Genom. Med. 2021;6:25. doi: 10.1038/s41525-021-00188-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hiz Kurul S., Oktay Y., Töpf A., Szabó N.Z., Güngör S., Yaramis A., Sonmezler E., Matalonga L., Yis U., Schon K., et al. High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases. Brain. 2022;145:1507–1518. doi: 10.1093/brain/awab395. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Dingemans A.J.M., Hinne M., Jansen S., van Reeuwijk J., de Leeuw N., Pfundt R., van Bon B.W., Vulto-van Silfhout A.T., Kleefstra T., Koolen D.A., et al. Phenotype based prediction of exome sequencing outcome using machine learning for neurodevelopmental disorders. Genet. Med. 2022;24:645–653. doi: 10.1016/j.gim.2021.10.019. [DOI] [PubMed] [Google Scholar]
- 14.Vohr B., Allan W.C., Scott D.T., Katz K.H., Schneider K.C., Makuch R.W., Ment L.R. Early-onset intraventricular hemorrhage in preterm neonates: incidence of neurodevelopmental handicap. Semin. Perinatol. 1999;23:212–217. doi: 10.1016/s0146-0005(99)80065-2. [DOI] [PubMed] [Google Scholar]
- 15.Moretti R., Pansiot J., Bettati D., Strazielle N., Ghersi-Egea J.F., Damante G., Fleiss B., Titomanlio L., Gressens P. Blood-brain barrier dysfunction in disorders of the developing brain. Front. Neurosci. 2015;9:40. doi: 10.3389/fnins.2015.00040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.De Haan T.R., Langeslag J., van der Lee J.H., van Kaam A.H. A systematic review comparing neurodevelopmental outcome in term infants with hypoxic and vascular brain injury with and without seizures. BMC Pediatr. 2018;18:147. doi: 10.1186/s12887-018-1116-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gilard V., Chadie A., Ferracci F.X., Brasseur-Daudruy M., Proust F., Marret S., Curey S. Post hemorrhagic hydrocephalus and neurodevelopmental outcomes in a context of neonatal intraventricular hemorrhage: an institutional experience in 122 preterm children. BMC Pediatr. 2018;18:288. doi: 10.1186/s12887-018-1249-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Sileo F.G., Zöllner J., D'Antonio F., Islam S., Papageorghiou A.T., Khalil A. Perinatal and long-term outcome of fetal intracranial hemorrhage: systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2022;59:585–595. doi: 10.1002/uog.24766. [DOI] [PubMed] [Google Scholar]
- 19.Cen Z., Chen Y., Chen S., Wang H., Yang D., Zhang H., Wu H., Wang L., Tang S., Ye J., et al. Biallelic loss-of-function mutations in JAM2 cause primary familial brain calcification. Brain. 2020;143:491–502. doi: 10.1093/brain/awz392. [DOI] [PubMed] [Google Scholar]
- 20.Schottlaender L.V., Abeti R., Jaunmuktane Z., Macmillan C., Chelban V., O'Callaghan B., McKinley J., Maroofian R., Efthymiou S., Athanasiou-Fragkouli A., et al. Biallelic JAM2 variants lead to early-onset recessive primary familial brain calcification. Am. J. Hum. Genet. 2020;106:412–421. doi: 10.1016/j.ajhg.2020.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Mochida G.H., Ganesh V.S., Felie J.M., Gleason D., Hill R.S., Clapham K.R., Rakiec D., Tan W.H., Akawi N., Al-Saffar M., et al. A homozygous mutation in the tight-junction protein JAM3 causes hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts. Am. J. Hum. Genet. 2010;87:882–889. doi: 10.1016/j.ajhg.2010.10.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Akawi N.A., Canpolat F.E., White S.M., Quilis-Esquerra J., Morales Sanchez M., Gamundi M.J., Mochida G.H., Walsh C.A., Ali B.R., Al-Gazali L. Delineation of the clinical, molecular and cellular aspects of novel JAM3 mutations underlying the autosomal recessive hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts. Hum. Mutat. 2013;34:498–505. doi: 10.1002/humu.22263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.O'Driscoll M.C., Daly S.B., Urquhart J.E., Black G.C.M., Pilz D.T., Brockmann K., McEntagart M., Abdel-Salam G., Zaki M., Wolf N.I., et al. Recessive mutations in the gene encoding the tight junction protein occludin cause band-like calcification with simplified gyration and polymicrogyria. Am. J. Hum. Genet. 2010;87:354–364. doi: 10.1016/j.ajhg.2010.07.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Abdel-Hamid M.S., Abdel-Salam G.M.H., Issa M.Y., Emam B.A., Zaki M.S. Band-like calcification with simplified gyration and polymicrogyria: report of 10 new families and identification of five novel OCLN mutations. J. Hum. Genet. 2017;62:553–559. doi: 10.1038/jhg.2017.4. [DOI] [PubMed] [Google Scholar]
- 25.Sobreira N., Schiettecatte F., Valle D., Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mutat. 2015;36:928–930. doi: 10.1002/humu.22844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Jin S.C., Dong W., Kundishora A.J., Panchagnula S., Moreno-De-Luca A., Furey C.G., Allocco A.A., Walker R.L., Nelson-Williams C., Smith H., et al. Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus. Nat. Med. 2020;26:1754–1765. doi: 10.1038/s41591-020-1090-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Saudi Mendeliome Group Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases. Genome Biol. 2015;16:134. doi: 10.1186/s13059-015-0693-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Abouelhoda M., Sobahy T., El-Kalioby M., Patel N., Shamseldin H., Monies D., Al-Tassan N., Ramzan K., Imtiaz F., Shaheen R., Alkuraya F.S. Clinical genomics can facilitate countrywide estimation of autosomal recessive disease burden. Genet. Med. 2016;18:1244–1249. doi: 10.1038/gim.2016.37. [DOI] [PubMed] [Google Scholar]
- 29.Fattahi Z., Beheshtian M., Mohseni M., Poustchi H., Sellars E., Nezhadi S.H., Amini A., Arzhangi S., Jalalvand K., Jamali P., et al. Iranome: A catalog of genomic variations in the Iranian population. Hum. Mutat. 2019;40:1968–1984. doi: 10.1002/humu.23880. [DOI] [PubMed] [Google Scholar]
- 30.Scott E.M., Halees A., Itan Y., Spencer E.G., He Y., Azab M.A., Gabriel S.B., Belkadi A., Boisson B., Abel L., et al. Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. Nat. Genet. 2016;48:1071–1076. doi: 10.1038/ng.3592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kars M.E., Başak A.N., Onat O.E., Bilguvar K., Choi J., Itan Y., Çağlar C., Palvadeau R., Casanova J.L., Cooper D.N., et al. The genetic structure of the Turkish population reveals high levels of variation and admixture. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2026076118. e2026076118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ishida T., Kundu R.K., Yang E., Hirata K.i., Ho Y.D., Quertermous T. Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo. J. Biol. Chem. 2003;278:34598–34604. doi: 10.1074/jbc.M304890200. [DOI] [PubMed] [Google Scholar]
- 33.Wegmann F., Petri B., Khandoga A.G., Moser C., Khandoga A., Volkery S., Li H., Nasdala I., Brandau O., Fässler R., et al. ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability. J. Exp. Med. 2006;203:1671–1677. doi: 10.1084/jem.20060565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hirata K.I., Ishida T., Penta K., Rezaee M., Yang E., Wohlgemuth J., Quertermous T. Cloning of an immunoglobulin family adhesion molecule selectively expressed by endothelial cells. J. Biol. Chem. 2001;276:16223–16231. doi: 10.1074/jbc.M100630200. [DOI] [PubMed] [Google Scholar]
- 35.Nasdala I., Wolburg-Buchholz K., Wolburg H., Kuhn A., Ebnet K., Brachtendorf G., Samulowitz U., Kuster B., Engelhardt B., Vestweber D., Butz S. A transmembrane tight junction protein selectively expressed on endothelial cells and platelets. J. Biol. Chem. 2002;277:16294–16303. doi: 10.1074/jbc.M111999200. [DOI] [PubMed] [Google Scholar]
- 36.Hara T., Ishida T., Cangara H.M., Hirata K.i. Endothelial cell-selective adhesion molecule regulates albuminuria in diabetic nephropathy. Microvasc. Res. 2009;77:348–355. doi: 10.1016/j.mvr.2009.01.002. [DOI] [PubMed] [Google Scholar]
- 37.Kobayashi H., Looker H.C., Satake E., Saulnier P.J., Md Dom Z.I., O'Neil K., Ihara K., Krolewski B., Galecki A.T., Niewczas M.A., et al. Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. Kidney Int. 2022;102:370–381. doi: 10.1016/j.kint.2022.04.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Gallardo-Vara E., Ruiz-Llorente L., Casado-Vela J., Ruiz-Rodríguez M.J., López-Andrés N., Pattnaik A.K., Quintanilla M., Bernabeu C. Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners. Cells. 2019;8:1082. doi: 10.3390/cells8091082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Xu B., Roos J.L., Dexheimer P., Boone B., Plummer B., Levy S., Gogos J.A., Karayiorgou M. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat. Genet. 2011;43:864–868. doi: 10.1038/ng.902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Collins R.L., Glessner J.T., Porcu E., Lepamets M., Brandon R., Lauricella C., Han L., Morley T., Niestroj L.M., Ulirsch J., et al. A cross-disorder dosage sensitivity map of the human genome. Cell. 2022;185:3041–3055.e25. doi: 10.1016/j.cell.2022.06.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.de Vries L.S., Koopman C., Groenendaal F., Van Schooneveld M., Verheijen F.W., Verbeek E., Witkamp T.D., van der Worp H.B., Mancini G. COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage. Ann. Neurol. 2009;65:12–18. doi: 10.1002/ana.21525. [DOI] [PubMed] [Google Scholar]
- 42.Yoneda Y., Haginoya K., Kato M., Osaka H., Yokochi K., Arai H., Kakita A., Yamamoto T., Otsuki Y., Shimizu S.i., et al. Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly. Ann. Neurol. 2013;73:48–57. doi: 10.1002/ana.23736. [DOI] [PubMed] [Google Scholar]
- 43.Meuwissen M.E.C., Halley D.J.J., Smit L.S., Lequin M.H., Cobben J.M., de Coo R., van Harssel J., Sallevelt S., Woldringh G., van der Knaap M.S., et al. The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature. Genet. Med. 2015;17:843–853. doi: 10.1038/gim.2014.210. [DOI] [PubMed] [Google Scholar]
- 44.Alavi M.V., Mao M., Pawlikowski B.T., Kvezereli M., Duncan J.L., Libby R.T., John S.W.M., Gould D.B. Col4a1 mutations cause progressive retinal neovascular defects and retinopathy. Sci. Rep. 2016;6:18602. doi: 10.1038/srep18602. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Zagaglia S., Selch C., Nisevic J.R., Mei D., Michalak Z., Hernandez-Hernandez L., Krithika S., Vezyroglou K., Varadkar S.M., Pepler A., et al. Neurologic phenotypes associated with COL4A1/2 mutations: Expanding the spectrum of disease. Neurology. 2018;91:e2078–e2088. doi: 10.1212/WNL.0000000000006567. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Srivastava S., Lewis S.A., Cohen J.S., Zhang B., Aravamuthan B.R., Chopra M., Sahin M., Kruer M.C., Poduri A. Molecular diagnostic yield of exome sequencing and chromosomal microarray in cerebral palsy: a systematic review and meta-analysis. JAMA Neurol. 2022;79:1287–1295. doi: 10.1001/jamaneurol.2022.3549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Lacoste B., Comin C.H., Ben-Zvi A., Kaeser P.S., Xu X., Costa L.d.F., Gu C. Sensory-related neural activity regulates the structure of vascular networks in the cerebral cortex. Neuron. 2014;83:1117–1130. doi: 10.1016/j.neuron.2014.07.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Andreone B.J., Lacoste B., Gu C. Neuronal and vascular interactions. Annu. Rev. Neurosci. 2015;38:25–46. doi: 10.1146/annurev-neuro-071714-033835. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Kugler E.C., Greenwood J., MacDonald R.B. The "neuro-glial-vascular" unit: the role of glia in neurovascular unit formation and dysfunction. Front. Cell Dev. Biol. 2021;9:732820. doi: 10.3389/fcell.2021.732820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Zisis E., Keller D., Kanari L., Arnaudon A., Gevaert M., Delemontex T., Coste B., Foni A., Abdellah M., Calì C., et al. Digital reconstruction of the neuro-glia-vascular architecture. Cereb. Cortex. 2021;31:5686–5703. doi: 10.1093/cercor/bhab254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Ouellette J., Toussay X., Comin C.H., Costa L.D.F., Ho M., Lacalle-Aurioles M., Freitas-Andrade M., Liu Q.Y., Leclerc S., Pan Y., et al. Vascular contributions to 16p11.2 deletion autism syndrome modeled in mice. Nat. Neurosci. 2020;23:1090–1101. doi: 10.1038/s41593-020-0663-1. [DOI] [PubMed] [Google Scholar]
- 52.Azmitia E.C., Saccomano Z.T., Alzoobaee M.F., Boldrini M., Whitaker-Azmitia P.M. Persistent angiogenesis in the autism brain: an immunocytochemical study of postmortem cortex, brainstem and cerebellum. J. Autism Dev. Disord. 2016;46:1307–1318. doi: 10.1007/s10803-015-2672-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Jann K., Hernandez L.M., Beck-Pancer D., McCarron R., Smith R.X., Dapretto M., Wang D.J.J. Altered resting perfusion and functional connectivity of default mode network in youth with autism spectrum disorder. Brain Behav. 2015;5:e00358. doi: 10.1002/brb3.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The published article includes all datasets generated or analyzed during this study. In particular, details of the variants are publicly available in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) with the following accession numbers: SCV002818296 (c.115del), SCV002818297 (c.287del), SCV002818299 (c.35T>A), and SCV002818300 (c.451+1G>A).